Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00568035
Recruitment Status : Completed
First Posted : December 5, 2007
Last Update Posted : January 8, 2009
Information provided by:
Quigley Pharma, Inc.

Brief Summary:
The purpose of this study is to determine whether QR-333 is safe and effective in the treatment of diabetic neuropathy as compared to placebo.

Condition or disease Intervention/treatment Phase
Diabetic Neuropathy Drug: QR-333 Phase 2

Detailed Description:

Diabetic neuropathy is among the most common complication of diabetes, resulting in pain and numbness, which affects the patients sleep, functioning and well-being. The pain is often accompanied by unpleasant sensations described as buzzing, cramp-like, burning, or jolting. The pain is usually symmetrical and occurs in the upper and lower extremities following a "glove and stocking" distribution.

To date there is no fully effective treatment for diabetic neuropathy. Therapy is tailored individually according to subject complaints and may be selected from categories including Non-steroidal anti-inflammatory drugs (NSAIDs) and adjuvant analgesics (including tricyclic antidepressants and anticonvulsants).

The clinical trial is being conducted to determine the safety and efficacy of QR-333 in the treatment of diabetic neuropathy as compared to placebo.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase II Study of QR-333 for the Treatment of Symptomatic Diabetic Peripheral Neuropathy
Study Start Date : December 2006
Actual Primary Completion Date : November 2008
Actual Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: QR-333 Drug: QR-333
QR-333 or placebo will be applied three times a day for 12 weeks
Placebo Comparator: Placebo Drug: QR-333
QR-333 or placebo will be applied three times a day for 12 weeks

Primary Outcome Measures :
  1. Determine the safety of a three times daily application of QR-333 as compared to placebo. [ Time Frame: 12 Weeks ]

Secondary Outcome Measures :
  1. Determine the efficacy of QR-333 on symptoms of diabetic neuropathy and the impact of QR-333 on the daily activities (including pain and sleep disturbance) of subjects with symptomatic diabetic neuropathy as compared to placebo. [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of diabetic neuropathy
  • must have some pain daily in the lower limbs due to diabetic polyneuropathy for at least 3 months prior to enrollment
  • must be willing to comply with study directions, write information in a diary (such as pain medications taken), read and comprehend written instructions, complete questionnaires, and have the ability to apply the cream as directed

Exclusion Criteria:

  • uncontrolled pain that has persisted for > 12 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00568035

United States, Alabama
Parkway Medical Center
Birmingham, Alabama, United States, 35215
Seale Harris Clinic / Alliance Clinical Research
Birmingham, Alabama, United States, 35216
United States, California
Pacific Sleep Medicine Services, Inc
Fountain Valley, California, United States, 92708
Advanced Medical Research, LLC
Lakewood, California, United States, 90712
Diablo Clinical Research, Inc.
Walnut Creek, California, United States, 94598
United States, Florida
Renstar Medical Research
Ocala, Florida, United States, 34471
Baptist Clinical Research
Pensacola, Florida, United States, 35201
Stedman Clinical Trails
Tampa, Florida, United States, 33613
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States, 33401
United States, Missouri
A&A Pain Institute
St. Louis, Missouri, United States, 63141
United States, New Jersey
New Brunswick, New Jersey, United States, 08903
Land Clinical Studies
West Caldwell, New Jersey, United States, 07006
United States, New York
Kaleida Health, Diabetes Center of WNY
Buffalo, New York, United States, 14209
United States, North Carolina
ECU Diabetes Research Center, Brody School of Medicine
Greenville, North Carolina, United States, 27834
United States, South Carolina
Hartwell Research Group / Anderson Family Care
Anderson, South Carolina, United States, 29621
United States, Texas
UT Southwestern Medical Center at Dallas
Dallas, Texas, United States, 75390
dgd Research
San Antonio, Texas, United States, 78229
Endeavor Clinical Trials, PA
San Antonio, Texas, United States, 78229
United States, Washington
Rainier Clinical Research Center, Inc
Renton, Washington, United States, 98057
Sponsors and Collaborators
Quigley Pharma, Inc.
Study Chair: Philip Raskin, MD University of Texas, Southwestern Medical Center at Dallas

Responsible Party: Quigley Pharma, Inc., Richard Rosenbloom Identifier: NCT00568035     History of Changes
Other Study ID Numbers: QR-333-002
First Posted: December 5, 2007    Key Record Dates
Last Update Posted: January 8, 2009
Last Verified: January 2009

Keywords provided by Quigley Pharma, Inc.:

Additional relevant MeSH terms:
Peripheral Nervous System Diseases
Diabetic Neuropathies
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases